LABT — Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Website: https://lakewoodamedex.com
Latest SEC filings for LABT
- 8-K — 2026-09-29
- EFFECT — 2026-09-25
- S-1 — 2026-09-18
- S-1 — 2026-09-18
- 424B3 — 2026-08-17
- 10-Q — 2026-08-14
- 8-K — 2026-07-15
- 424B3 — 2026-06-22
- 424B3 — 2026-06-22
- 8-K — 2026-06-17
Latest LABT news
- — Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds (prnewswire.com)
- — Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences (prnewswire.com)
- — A topical candidate showed lab activity against drug-resistant bacteria from foot ulcers - Stock Titan (Stock Titan)
- — Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers (prnewswire.com)
- — Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media (Kalkine Media)
- — Lakewood-Amedex Biotherapeutics Inc. SEC Filing (Sep 25, 2026) - Stock Titan (Stock Titan)
Educational tool only — not investment advice.